Medical management of heart failure secondary to coronary artery disease

Coronary Artery Disease

Volumn 9, Issue 10, 1998, Pages 659-674

  Challapalli, Sridevi ^a   Bonow, Robert O ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Coronary artery disease; Heart failure

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; INOTROPIC AGENT; NITRATE;

CORONARY ARTERY DISEASE; HEART FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0031650671     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809100-00006     Document Type: Review

References (216)

1. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease: the Framingham Heart Study. N Engl J Med 1990; 322:1635-1641.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990; 150:769-773.
3. American Heart Association. Heart and stroke facts: 1996 statistical supplement. Page 15.
4. CDC. Trends in ischemic heart disease mortality-United States, 1980-1988. MMWR 1992; 41:548-549,555-556.
5. Eriksson H. Heart failure: a growing public health problem. J Intern Med 1995; 237:135-141.
6. National Center for Health Statistics. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1990. Vital and health statistics. Series 13, No. 113. Hyattsville, MD: The Center; 1992. DHHS publication No. 92-1774.
7. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971; 285:1441-1446.
8. Massie BM, Shah NB. The heart failure epidemic. Curr Opin Cardiol 1996; 11:221-226.
9. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22 (suppl A):6A-13A.
10. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88:107-115.
11. Clinical Practice Guidelines. Heart Failure: Evaluation and care of patients with left ventricular systolic dysfunction. Rockville, MD: US Dept of Health and Human Services. 1994:11-23, AHCPR publication no. 940612.
12. Williams JF Jr, Bristow MR, Fowler MB, Francis GR, Garson A, Gersh BJ, et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26:1376-1398.
13. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation. 1985; 72:681-685.
14. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s: Evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993; 22 (suppl A):3A-5A.
15. Bourassa MG, Gurné O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, et al., for the The Studies of Left Ventricular Dysfunction (SOLVD) investigators. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 22 (suppl A):14A-19A.
16. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation 1998; 97:282-289.
17. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harson WE, Tristani FE, Dunkman WB. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
18. The CONSENSUS Trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
19. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320:677-683.
20. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
21. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
22. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al., for the PROMISE study research group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-1475.
23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
24. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. for the RADIANCE Study Group. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329:1-7.
25. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329:149-155.
26. Singh SN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazerri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333:77-82.
27. Packer M, Bristow MR, Conn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
28. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-1114.
29. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
30. Bart BA, Shaw LK, McCants CB, Fortin DF, Lee KL, O'Connor CM. The clinical and angiographic diagnosis of ischemic cardiomyopathy: a need to reassess our diagnostic criteria [abstract]. Circulation 1996; 949 (suppl 1):1-338.
31. Bart BA, Shaw LK, McCants CB, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or non-ischemic cardiomyopathy. J Am Coll Cardiol 1997; 30:1002-1008.
32. Smith WM. Epidemiology of congestive heart failure. Am J Cardiol 1985; 55 (suppl A):3A-8A.
33. Colucci WS and Braunwald E. Pathophysiology of Heart Failure. In Braunwald E (editor): Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 1997. pp. 394-402.
34. Mills R and Pepine CJ. Heart failure secondary to coronary artery disease. In Hosenpud JD and Greenberg BH (editors): Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management. New York: Springer Verlag; 1993. pp. 177-195.
35. Cohn JN. The management of chronic heart failure. N Engl J Med 1996; 335:490-498.
36. Edwards NC, Sinusas AJ, Bergin JD, Watson DD, Ruiz M, Beller GA. Influence of subendocardial ischemia on transmural myocardial function. Am J Physiol 1992; 262:H-568-H-576.
37. Unverferth DV, Magonen RD, Lewis RP, Leier CV. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983; 105:176-179.
38. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, et al. for the SOLVD Investigators. Relation of neurohumoral activatin to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. J Am Coll Cardiol 1994; 23:1410-1420.
39. Rockman HA, Juneau C, Chatterjee K, Rouleau JL. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989; 64:1344-1348.
40. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254.
41. Paulus WJ, Vantrimpont PJ, Shah AM. Paracine coronary endothelial control of left ventricular function in humans. Circulation 1995; 92:2119-2126.
42. Shen W, Hintze TH, Wolin MS. Nitric oxide: an important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 1995; 92:3505-3512.
43. Guarda E, Karwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993; 27:2130-2134.
44. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation 1995; 92:3337-3349.
45. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93:1214-1222.
46. Harrison DG, Freiman PC, Mitchell GG, Armstrong ML, Marcus ML, Heistad DD. Alterations of vascular reactivity in atherosclerosis. Circ Res 1987; 61 (suppl II):II-74-II-80.
47. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989; 80:458-465.
48. Dzau VJ, Gibbons GH, Cooke DP, Omoigui N. Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives. Circulation 1993; 87:705-719.
49. Loscalzo J, Vita JA. Ischemia, hyperemia, exercise, and nitric oxide: complex physiology and complex molecular adaptations. Circulation 1994; 90:2556-2559.
50. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1994; 89 (suppl 1):87-102.
51. Lüscher TF, Boulanger DM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension 1992; 19:117-130.
52. Levin ER. Endothelins. N Engl J Med 1995; 333:356-363.
53. Krüger D, Sheikhzadeh A, Giannitsis E, Stierle U. Cardiac release and kinetics of endothelin after severe short-lasting myocardial ischemia. J Am Coll Cardiol 1997; 30:942-946.
54. Treasure CB, Alexander RW. The dysfunctional endothelium in heart failure. J Am Coll Cardiol 1993; 22 (suppl A):129A-134A.
55. Colucci WS. Myocardial endothelin: does it play a role in myocardial failure? Circulation 1996; 93:1069-1072.
56. Gheorghiade M. Digoxin. Cardiology Clinics: Annual of Drug Therapy 1997; 1:81-103.
57. Starr I, Luchi RJ. Blind study on the action of digitoxin in elderly women. Am Heart J 1969; 78:740-751.
58. Dobbs SN, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure. Placebo controlled trial in outpatients. Br Med J 1977; 1:749-752.
59. Gheorghiade M, St. Clair J, St. Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987; 9:849-857.
60. Alicandri C, Fariello R, Boni E, Zaninelli A, Castellano M, Beschi M, et al. Captopril versus digoxin in mild-moderate heart failure: a cross-over study. J Cardiovasc Pharmacol 1987; 9 (suppl 3):S61-S67.
61. Guyatt GH, Sullivan MJJ, Fallen EL, Tihal H, Rideout E, Halcrow S, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61:371-375.
62. Gheorghiade M, Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation 1991; 84:2181-2186.
63. Krum H, Bigger JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25:289-294.
64. Van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans, S, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22:1564-1573.
65. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempt JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989; 80:65-77.
66. Brouwer J, Van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Boomsma F, Haaksma J, Lie XI. For the Dutch Ibopamine Multicenter Trial (DIMT) Study Group. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. J Am Coll Cardiol 1995; 26:283-290.
67. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure. Results of the PROVED Trial. J Am Coll Cardiol 1993; 22:955-962.
68. Gheorghiade M, Young JB, Uretsky B, Havstad S. Tilley B on behalf of the PROVED and RADIANCE Investigators. Predicting clinical deterioration after digoxin withdrawal in heart failure [abstract]. Circulation 1993; 88:1-604.
69. Gheorghiade M, Zarowitz B. Review of randomized trials of digoxin therapy in patients with chronic heart failure. Am J Cardiol 1992; 69:48G-63G.
70. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259:539-544.
71. Gheorghiade M, Young JB, Uretsky BF, Haustad S, Tilley B, on behalf of the PROVED and RADIANCE Investigators. The effects of digoxin withdrawal in patients with stable heart failure due to CAD compared to primary cardiomyopathy. Insights from the PROVED and RADIANCE Studies [abstract]. Circulation 1995; 92:1-142.
72. Digitalis Investigatin Group. Rationale, design, implementation, and baseline characteristics of patients in DIG Trial: a large, simple, long-term trial to evaluation the effect of digitalis on mortality in heart failure. Controlled Clin Trials 1996; 17:77-97.
73. Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) Trial: a stimulus for further research. Am Heart J 1997; 134:3-12.
74. Moss AJ, Davis HT, Conrad DL, DeCamilla JJ, Odoroff CL. Digitalis associated cardiac mortality after myocardial infarction. Circulation 1981; 64:1150-1155.
75. Bigger AJ, Fleiss JL, Rolnitzky LA, Merab JP, Ferrick KJ. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985; 55:623-630.
76. Sweeney MO, Moss AJ, Eberly S, Andrews M. Factors associated with sudden cardiac death in survivors of acute myocardial infarction [abstract]. Circulation 1991; 84 (suppl 4):II-20.
77. Ryan TJ, Bailey KR, McCabe CH, Luk S, Fisher LD, Mock MB, Killip T. The effects of digitalis on survival in high-risk patients with coronary artery disease. Circulation 1983; 67:735-742.
78. Byington R, Goldstein S, for the BHAT Research Study Group. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the Beta-Blocker Heart Attack Trial. J Am Coll Cardiol 1985; 6:976-982.
79. Muller JE, Turi ZG, Stone PH, Rude RE, Raabe DS, Jaffe AS, Gold HK, et al. Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study. N Engl J Med 1986; 314:265-271.
80. Madsen EB, Gilpin E, Henning H, Ahnve S, LeWinter M, Mazur J, et al. Prognostic importance of digitalis after myocardial infarction. J Am Coll Cardiol 1984; 3:681-689.
81. +) -ATPase and cardiac glycoside binding. J Clin Invest 1976; 57:341-350.
82. Lynch JJ, Montgomery DG, Lucchesi BR. Facilitatin of lethal ventricular arrhythmias by therapeutic digoxin in conscious postinfarction dogs. Am Heart J 1986; 111:883-890.
83. Lynch JJ, Luchesi BR. Effect of digoxin on the extent of injury and the severity of arrhythmias during acute myocardial ischemia and infarction in the dog. J Cardiovasc Pharmacol 1988; 11:193-203.
84. Smith TX, Kelly RA, Stevenson LW, Braunwald E. Management of Heart Failure. In Brunwald E (editor): Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders Company; 1997. p. 501.
85. Dyckner T, Wester P. Salt and water balance in congestive heart failure. Acta Med Scand 1986; 707 (suppl):27-31.
86. Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 2:709-711.
87. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114:886-894.
88. Dahlstrom U, Kartsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 1993; 71:29A-33A.
89. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985; 102:314-318.
90. Kupper AJ, Fintelman H, Huige MC, Liem KL, Lustermans FA. Cross-over comparison of the fixed combination of furosemide and triamterene and the free combination of furosemide and triamterene in the maintenance treatment of congestive heart failure. Eur J Clin Pharmacol 1986; 30:342-343.
91. Cleland JG, Gillen G, Dargie JH. The effects of furosemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal hemodynamics in heart failure. Eur Heart J 1988; 9:132-141.
92. Wilson JR, Untereker W, Hirshfeld J. Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure. Am J Cardiol 1981; 48:934-938.
93. Pierpont GL, Chohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Chest 1978; 73:8-13.
94. Franciosa JA, Cohn JN. Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure. Circulation 1979; 59:1085-1091.
95. Nelson GI, Ahuja RC, Silke B, Hussain M, Taylor SH. Arteriolar or venous dilatation in left ventricular failure following acute myocardial infarction: a hemodynamic trial of hydralazine and isosorbide dinitrate. J Cardiovasc Pharmacol 1983; 5:574-579.
96. Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol 1977; 40:794-801.
97. Massie BM, Kramer B, Shen E, Haughom F. Vasodilator treatment with isosorbide-dinitrate and hydralazine in chronic heart failure. Br Heart J 1981; 45:376-384.
98. Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol 1989; 63:461-464.
99. Chatterjee K, Massie B, Rubin S, Gelberg H, Brundage BH, Ports TA. Longterm outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise. Am J Med 1978; 65:134-135.
100. Daly P, Rouleau JL, Cousineau D, Burgess JH, Chatterjee K. Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe heart failure. Br Heart J 1986; 56:152-157.
101. Cohn J. Nitrates are effective in the treatment of chronic congestive heart failure: the protagonist's view. Am J Cardiol 1990; 66:444-446.
102. Leier CV, Huss PM, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous intolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983; 67:817-822.
103. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991; 114:667-677.
104. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19:842-850.
105. Franciosa JA, Weber KT, Levine TB, Kinasewitz GT, Janick JS, West J, et al. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J 1982; 104:587-594.
106. Conradson TB, Ryden L, Ahlmark G, Saetre H, Persson S, Nyquist O, Wernersson G. Clinical efficacy of hydralazine in chronic heart failure: one year double-blind placebo controlled study. Am Heart J 1984; 108:1001-1006.
107. Haq A, Rakowski H, Baigri R, McLaughlin P, Burns R, Tihal H, et al. Vasodilatory therapy in refractory congestive heart failure: a comparative analysis of hemodynamic and noninvasive studies. Am J Cardiol 1982; 49:439-444.
108. Packer M, Meller J, Medina N, Yushak M, Gorlin R. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure: clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. Am J Cardiol 1981; 48:939-945.
109. Roden DM. Cardiovascular news. Cardiovascular and Renal Advisory Panel of the U.S. Food and Drug Administration consider four drugs. Circulation 1997; 95:2335-2337.
110. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984; 144:1947-1953.
111. Zusman RM. Renin- and non-renin-mediated antihypertensive actions of converting-enzyme inhibitors. Kidney Int 1984; 25:969-983.
112. Tewksbury DA. Angiotensinogen: biochemistry and molecular biology. In Laragh JH and Brenner BM (editors): Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1990. pp. 1197-1216.
113. Reffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
114. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
115. Kober L, Torp-Pederson C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-1676.
116. Kleber FX, Niemoller L, Fischer M, Doering W. Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition. Am J Cardiol 1991; 68:121-126.
117. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK. Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
118. Foult JM, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation 1988; 77:337-344.
119. Pfeffer M, Lamas GA, Vaughn DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988; 319:80-86.
120. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15 (suppl 6):S20-S24.
121. Brown N, Vaughan DE. Angiotension-converting enzyme inhibitors. Circulation 1998; 97:1411-1420.
122. Pohl U. Role of endothelium-derived nitric oxide in the control of local blood flow under physiological and pathophysiological conditions. Can J Cardiol 1993; 9 (suppl C):6C-11C.
123. James IM, Dickenson EJ, Burgoyne W, Jeremy JY, Barrados MA, Mikhailidis DP, Dandona P. Treatment of hypertension with captopril: Preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988; 2:21-25.
124. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effects of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984; 6:840-843.
125. Vaughan DE, Shen C, Lazos SA. Angiotensin II induces secretion of plasminogen activator inhibitor (PAI-1) in vitro [abstract]. Circulation 1992; 86 (suppl I):I-557.
126. Olson Jr JA, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Neurobiology 1991; 88:1928-1932.
127. Luskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9:87-115.
128. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992; 3:285-290.
129. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94:258-265.
130. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341:1496-1500.
131. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzucki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
132. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
133. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
134. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678-684.
135. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 1996; 27:337-344.
136. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669-685.
137. Yusuf S, Pepine CJ, Garces C, Pouler H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173-1178.
138. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, et al. on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation 1994; 90:1731-1738.
139. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. on behalf of the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
140. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, et al. Combination neurohumoral blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure:design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997; 13 (suppl 12):1166-1174.
141. Willich SN, Linderer T, Wegscheider K, Leizorovicz A, Alamercery I, Schröder R. Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior β-adrenergic blockade. Circulation 1989; 80:853-858.
142. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30:27-34.
143. Eichhorn E, Bristow MR. Practical guidelines for initiation of beta adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79:794-798.
144. Gheorghiade M, Benatar D, Konstam MA, Stoukides CA, Bonow RO. Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. Am J Cardiol 1997; 80 (suppl 8B):14H-27H.
145. Waagstein F, Bristow M, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342:1441-1446.
146. CIBIS Investigators and Committees. A randomized trial of blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:1765-1773.
147. Rapaport E, Gheorghiade M. Pharmacologic therapies after myocardial infarction. Am J Med 1996; 101 (suppl 4A):61S-70S.
148. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981; ii:823-827.
149. The MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985; 6:199-226.
150. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 1:57-66.
151. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801-807.
152. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 274:1707-1714.
153. Bristow MR, Gilbert EM, Abraham WT, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94:2807-2816.
154. Packer M, Colucci WS, Sackner-Bernstein JD, Hattler B, White M, Mealy P, et al. for the PRECISE Study Group. Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94:2793-2799.
155. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94:2817-2825.
156. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular ejection function and survival in subjects with chronic heart failure. Circulation 1996; 94:2807-2816.
157. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94:2800-2806.
158. Francis GS. Calcium channel blockers and congestive heart failure. Circulation 1991; 83:336-338.
159. Elkayam U, Shotan A, Mehra A, Ostrzega E. Calcium channel blockers in heart failure. J Am Coll Cardiol 1993; 22 (suppl A):139A-144A.
160. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989; 80 (suppl IV):IV-59-IV-67.
161. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319:385-393.
162. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective randomized, double-blind, crossover study to compare the efficcy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82:1954-1961.
163. Benatar D, Hall V, Reddy S, Gheorghiade M. Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. Am J Therap 1998; 5:25-32.
164. Cohn JN, Ziesche SM, Loss LE, Anderson GF and the V-HeFT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT VIII. Circulation 1995; 92 (suppl I):I-143.
165. The Danish Study on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II [DAVIT II]). Am J Cardiol 1990; 66:779-785.
166. Estacio R, Jeffers BW, Hiatt WR, Bigerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
167. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Suppression Trial. N Engl J Med 1991; 324:781-788.
168. Simes PA, Overskeid K, Pedersen TR, Bathen J, Drivenes A, Froland GS, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: Norwegian Nifedipine Multicenter Trial. Circulation 1984; 70:638-644.
169. Wilcox RG, Hampton JR, Banks DC, Birkhead JS, Brooksby IA, Burns-Cox CJ, et al. Trial of early nifedipine in acute myocardial infarction. The TRENT study. MBJ 1986; 293:1204-1208.
170. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9:354-364.
171. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) II: design, methods and results [abstract]. Bur Heart J 1988; 9 (suppl 1):350.
172. Report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit. A randomized, double-blind placebo-controlled comparison of recurrent ischemia in patients with nifedipine or metoprolol or both. Br Heart J 1986; 56:400-414.
173. Gheorghiade M, Goldstein S. Calcium-channel blockers in post mycoardial infarction patients with special notation to the Danish Verapamil Infarction Trial II. Progress in Cardiovasc Dis 1991; 34:37-43.
174. The Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarction. Eur Heart J 1984; 5:516-528.
175. Levin TB for the MACH-1 Investigators. The design of the Mortality Assessment in Congestive heart Failure trial (MACH-1, Mibefrodil). Clin Cardiol 1997; 20:320-326.
176. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336:1-6.
177. Massie B, Bourassa M, DiBianco R, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Long-term oral amrinone for congestive heart failure: Lack of efficacy in multicenter controlled trial. Circulation 1985; 71:963-971.
178. Packer M, Carver JR, Rodeheffer RJ, Dec GW, Leier CV, Benotti J, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-1475.
179. Uretsky BF, Jessup M, Konstam MA, et al. for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with mild to moderate to moderately severe congestive heart failure: Lack of benefit compared with placebo. Circulation 1990; 82:774-780.
180. Hamptom JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, et al. for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349:971-977.
181. The Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76:223-231.
182. Cohn JN. VEST results. Presented at the XIIth Plenary Session of the 69th Scientific Session of the American Heart Association, New Orleans, LA, Nov. 10-13, 1996.
183. Reddy S, Benatar D, Gheorghiade M. Update on digoxin and other oral positive inotropic agents for chronic heart failure. Curr Opin Cardiol 1997; 12:233-241.
184. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M and the PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study [abstract]. Circulation 1993; 88:1-501.
185. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
186. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. for the SWORD investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348:7-12.
187. Doval HD, Nul DR, Grancelli HO, Perrone S, Bortman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344:493-498.
188. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674.
189. Cairns JA, Connolly SJ, Roberts R, Gent M, for the CAMIAT investigators. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. Am J Cardiol 1993; 72:87F-94F.
190. Cairns JA, Connolly SJ, Roberts R, Aent M for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive premature depolarizations: CAMIAT. Lancet 1997; 349:675-682.
191. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii:349-360.
192. Aspirin Myocardial Infarction Study Research Group. A randomized trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243:661-669.
193. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994; 343:499-503
194. Antiplatelet Trialists'Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308:81-106.
195. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309:396-403.
196. Cairns JA, Gent M, Singer J, Finnei KJ, Froggatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313:1369-1375.
197. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111.
198. The RISC Group: Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disesase. Lancer 1990; 336:827-830.
199. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: longterm effects on the risk of myocardial infarction, occurrence of severe angina and the need for revascularization: Research Group on Instability and Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18:1587.
200. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L. et al. Antithrombotic therapy and progression of coronary artery disease. Circulation 1992; 86 (suppl III):III-100-III-110.
201. Juul-Moller S, Evardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R, et al. for the Swedish Angina Pectoris Aspirin Trial (SAPAT): double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectors. Lancet 1992; 340:1421-1425.
202. Goldstein RE, Andrews M, Hall WJ, Moss AJ, for the Multicenter Myocardial Ischemia Research Group. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996; 28:326-330.
203. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infaction: subgroup analysis of the Cooperative New Scnandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79:115-119.
204. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20:1549-1555.
205. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival : a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31:419-425.
206. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 1996; 93:357-365.
207. Smith P, et al. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147-152.
208. Dries DL, Domanski MJ, Waclawiw MA, Gersh BL. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997; 79:909-913.
209. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93:1262-1277
210. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31:749-753.
211. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350:389-396.
212. Prie CA. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CARRIE). Lancet 1996; 348:1329-1339.
213. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastain on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
214. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, et al. for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93:1796-1802.
215. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
216. Kjekshus J, Pedersen TR, Olsson AG, Faeryeman O, Pyorala K. Effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Failure 1997; 3:249-254.